opthea
announces
pricing
initial
public
offering
united
states
melbourne
australia
globe
newswire
opthea
limited
asx
opt
nasdaq
opt
clinical
stage
biopharmaceutical
company
developing
novel
therapy
treat
highly
prevalent
progressive
retinal
diseases
today
announces
pricing
initial
public
offering
united
states
offering
american
depositary
shares
ads
representing
ordinary
shares
initial
public
offering
price
us
per
ads
underwriting
discounts
commissions
addition
lieu
adss
company
offered
sold
certain
investors
warrants
purchase
adss
public
offering
price
us
per
warrant
represents
initial
public
offering
price
per
ads
minus
us
per
ads
exercise
price
warrant
aggregate
gross
proceeds
company
expected
approximately
us
million
company
also
granted
underwriters
option
purchase
additional
adss
initial
public
offering
price
per
ads
less
underwriting
discounts
commissions
adss
expected
begin
trading
nasdaq
global
select
market
october
ticker
symbol
offering
expected
close
october
subject
satisfaction
customary
closing
conditions
citigroup
svb
leerink
acting
joint
managers
offering
oppenheimer
truist
securities
acting
lead
managers
registration
statement
relating
securities
declared
effective
securities
exchange
commission
sec
october
offering
made
means
prospectus
copies
final
prospectus
relating
describing
terms
offering
available
may
obtained
citigroup
global
markets
c
broadridge
financial
solutions
long
island
avenue
edgewood
ny
telephone
svb
leerink
llc
attention
syndicate
department
one
federal
street
floor
boston
telephone
ext
email
syndicate
press
release
constitute
offer
sell
solicitation
offer
buy
securities
jurisdiction
shall
constitute
offer
solicitation
sale
jurisdiction
offer
solicitation
sale
would
unlawful
prior
registration
qualification
securities
laws
jurisdiction
opthea
opthea
asx
opt
nasdaq
opt
biopharmaceutical
company
developing
novel
therapy
address
unmet
need
treatment
highly
prevalent
progressive
retinal
diseases
including
wet
macular
degeneration
wet
amd
diabetic
macular
edema
dme
opthea
lead
product
candidate
developed
use
combination
monotherapies
achieve
broader
inhibition
vegf
family
goal
improving
overall
efficacy
demonstrating
superior
vision
gains
achieved
inhibiting
alone
inherent
risks
investment
biotechnology
companies
number
inherent
risks
associated
development
pharmaceutical
products
marketable
stage
lengthy
clinical
trial
process
designed
assess
safety
efficacy
drug
prior
commercialization
significant
proportion
drugs
fail
one
criteria
risks
include
uncertainty
patent
protection
proprietary
rights
whether
patent
applications
issued
patents
offer
adequate
protection
enable
product
development
obtaining
necessary
drug
regulatory
authority
approvals
difficulties
caused
rapid
advancements
technology
companies
opthea
dependent
success
research
development
projects
ability
attract
funding
support
activities
investment
research
development
projects
assessed
fundamentals
trading
manufacturing
enterprises
therefore
investment
companies
specializing
drug
development
must
regarded
highly
speculative
opthea
strongly
recommends
professional
investment
advice
sought
prior
investments
statements
certain
statements
announcement
may
contain
statements
including
within
meaning
private
securities
litigation
reform
act
regarding
company
business
well
proposed
offering
statement
describing
company
goals
expectations
intentions
beliefs
including
relate
proposed
offering
expected
closing
statement
considered
statement
statements
subject
certain
risks
uncertainties
including
market
conditions
satisfaction
customary
closing
conditions
relating
offering
impact
general
economic
industry
political
conditions
australia
united
states
internationally
risks
uncertainties
described
fully
section
titled
risk
factors
final
prospectus
related
offering
filed
sec
company
undertakes
obligation
publicly
update
statement
whether
result
new
information
future
events
otherwise
except
required
applicable
law
place
undue
reliance
statements
predictions
future
events
statements
apply
date
announcement
actual
results
could
differ
materially
discussed
asx
announcement
